Intendis GmbH v. Glenmark Pharmaceuticals Inc., No. 15-1902 (Fed. Cir. May 16, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This case arises under the Hatch –Waxman Act, 1 and involves Glenmark Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Inc., USA ’s (collectively, “Glenmark”) 2 proposed generic version of Finacea® Gel, a topical med i- cation for various skin disorders. Glenmark appeals the United States District Court for the District of Delaware ’s final judgment entered in favor of Intendis GmbH , In- traserv GmbH & Co. KG, and Bayer HealthCare Pharma- ceuticals Inc. (collectively, “Appellees” ). For the reasons set forth below, we affirm.